Pharma sales reps are increasingly turning to consumer-grade tools and off-channel communications, which can lack both the controls and the oversight needed for confident compliance. These actions:
- Undermine governance strategies
- Create ethical dilemmas
- Increase risk of noncompliance
Rather than attempting to find and ban off-channel communications happening in the dark, firms should implement the tools and training necessary to bring these conversations into the light of compliance.
Key regulatory risks for pharma sales reps
Compliance teams in life sciences are under pressure to meet two separate demands:
- They must manage how sales reps communicate, ensuring that communications are secure, representative, and authorized.
- They must also capture, archive, and monitor records of these interactions, and be able to make them available to satisfy regulatory exams.
Below are some but not all of the key rules and risks pertaining to life sciences field operations from U.S. regulatory and enforcement agencies like the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), and the Department of Justice (DOJ).
Health Insurance Portability and Accountability Act (HIPAA)
Rule: Patient health information (PHI) may only be accessed, shared, or stored through HIPAA-compliant channels. Employees handling PHI, such as pharma sales reps must abide by specific retention, access, and security terms.
Risk: Under pressure to respond quickly, a sales rep sends patient data to a healthcare professional (HCP) via an unsecure channel such as a personal WhatsApp, creating an authorized disclosure with no retrievable record.
Example consequence: Substantial civil monetary penalties (up to nearly $2M per violation category per year), mandatory breach notification to affected patients, and potential placement on the HHS’s public breach list.
False Claims Act (FCA)
Rule: The FCA imposes liability on anyone who knowingly submits, or causes the submission of, a false or fraudulent claim to a federal healthcare program. In pharma sales, this most commonly arises from off-label promotion, undisclosed kickbacks, or self-referrals that render a reimbursement claim fraudulent.
Risk: A sales rep messages an HCP unapproved promotional content encouraging off-label use, and the resulting prescriptions are billed to Medicare.
Example Consequence: Off-label promotion that results in false claims has historically resulted in multi-billion-dollar settlements. In March 2025, one company was fined $1.64 billion for FCA violations resulting from off-label promotions.
Federal Food, Drug, and Cosmetic Act (FDCA) Section 301
Rule: FDCA §301 prohibits the introduction of misbranded drugs into commerce. Companies are responsible for the promotional conduct of their sales reps and must supervise communications with HCPs to prevent misbranding violations.
Risk: A sales rep shares an unsanctioned product summary via personal email to an HCP — content never reviewed by compliance — constituting misbranding that cannot be retrieved or audited after the fact.
Example Consequence: Under the Park Doctrine, executives can be held criminally liable for the rep’s lack of supervision, even if they had no direct knowledge of the misconduct.
21 Code of Federal Regulations (CFR) Part 11
Rule: Electronic records used in FDA-regulated activities must be trustworthy, reliable, and tamper-evident. Organizations must enforce audit trails, access controls, and WORM (write once, read many) storage to ensure records cannot be altered without detection.
Risk: A sales rep records HCP interactions in a personal notes application or editable spreadsheet with no access controls or activity log, making it impossible to produce a verified, unaltered record of the interaction during an FDA inspection.
Example Consequence: The FDA may halt all promotional activity until a compliant, verifiable recordkeeping system is implemented, potentially creating significant operational disruption.
Anti-Kickback Statute (AKS)
Rule: Pharma companies and their employees are prohibited from offering, paying, soliciting, or receiving anything of value to induce or reward prescriptions, referrals, or recommendations reimbursable by federal healthcare programs.
Risk: Electronic communications records document sales reps coordinating meals, speaker fees, entertainment, or other remuneration for an HCP with value far exceeding what is appropriate.
Example Consequence: Offending companies may incur civil monetary penalties of up to $100,000 per violation plus three times the remuneration amount, exclusion from federal healthcare programs, or criminal prosecution. AKS violations routinely accompany FCA charges, significantly compounding liability.
Sunshine Act
Rule: Pharmaceutical companies must report to CMS any payment or transfer of value made to physicians and teaching hospitals, including meals, speaker fees, consulting arrangements, and travel above the annual de minimis threshold.
Risk: A sales rep arranges an HCP meal via WhatsApp, bypassing the company’s expense tracking system. Even if WhatsApp is a monitored channel, proper documentation must still be submitted via the CMS Open Payments report.
Example Consequence: Tiered civil monetary penalties apply for failures to report, with significantly higher exposure for knowing violations, plus reputational risk when unreported payments are later identified publicly.
Prescription Drug Marketing Act (PDMA)
Rule: Sales reps who distribute drug samples must obtain a signed request from a licensed practitioner before each distribution and maintain complete electronic records of all sample transactions in a system that produces a verifiable audit trail.
Risk: A sales rep confirms sample drop-offs via text message rather than logging them in the company’s sample management system, leaving sample transactions unrecorded and unreconcilable during an audit.
Example Consequence: Unrecorded drop-offs can result in criminal penalties, product seizure, and injunctions. Recurring accountability failures are a frequent trigger for FDA Warning Letters and can prompt broader compliance investigations.
DOJ Evaluation of Corporate Compliance Programs (ECCP)
Rule: Companies must retain all business-related communications and prohibit off-channel applications that circumvent recordkeeping. The DOJ actively assesses whether compliance programs are effective.
Risk: Sales reps use ephemeral messages on WhatsApp to discuss product positioning with HCPs, impeding the ability to produce a record of the conversation during a government investigation.
Example Consequence: Use of ephemeral messaging may be treated as deliberate obstruction, resulting in loss of cooperation credit and exposure to the full range of available penalties.
State Laws
Rule: Many states impose their own pharmaceutical marketing disclosure requirements, with differing thresholds and reporting timelines. Companies must track and report transfers of value to HCPs on a state-by-state basis.
Risk: A sales rep communicates and confirms a promotional interaction with an HCP off-channel, resulting in a state-reportable transfer of value with no electronic record to support disclosure obligations.
Example Consequence: Settlement action includes state-level fines, mandatory corrective reporting, and reputational damage from public disclosure. Non-compliance across multiple states significantly compounds exposure.
How to maintain compliant communications across the field
To ensure compliant Organizations should evaluate the impact of employee training, work to foster a compliant culture, and review their governance strategy to ensure compliant communications.
Training your staff
Effective training requires moving from passive e-learning scenarios to real-life simulations that reflect the high-pressure reality of the job. You can’t rely on staff to simply memorize the rules. Instead, immerse them in authentic scenarios that test their ability to apply compliance principles under pressure.
For example, a field rep receives a request from a doctor for a quick off-label update on WhatsApp. Compliance training should outline how to pivot the conversation back to a secure, archived channel and focus on why the rules exist.
Culture and conduct
A truly compliant culture is one where ephemeral messages are viewed as an existential threat to the company’s ability to receive cooperation credit. It starts at the top: leadership must signal zero tolerance for unapproved communications.
If a manager ignores the use of personal Apple® iMessages for business-related updates, for example, they are fostering a culture of willful neglect. True operational resilience means encouraging internal reporting so that violations are caught, and dealt with, before they‘re brought to light by auditors or whistleblowers.
Governance and policies
Having the right data governance and policies in place can provide protection against blind spots and help improve overall compliance workflows. However, this must be built upon the full scale of the various regulatory requirements, moving beyond minimum actions and towards prudential policies.
For example, it’s worth conducting a channel audit to catalogue every app on both workplace and personal devices, refreshing your bring-your-own-device (BYOD) policy to align with (or exclude) all communication channels used by employees.
Capturing, storing, and monitoring communications compliantly
Compliant communications can come under risk when employees are faced with unexpected technical limitations.
Field reps often face significant technical limitations that can impede their productivity. A lack of cell connectivity in rural areas can drive employees to conduct outreach on unauthorized channels; so can a buggy update that causes an app to go offline. Switching between multiple approved apps, or a lack of cell connectivity in rural clinics are two common driving forces towards moving to unauthorized channels.
Healthcare professionals (HCPs) want to communicate on the channels they’re most comfortable using. We know that a quick message on WhatsApp can be tempting, which is why compliance teams must put the proper tools in place to mitigate this, and the other risks detailed.
Integrate mobile-first technology solutions that enable sales teams to work most effectively while adhering to regulatory requirements. Features to prioritize include:
- Capture at source: solutions should allow sales reps to use familiar interfaces while automatically capturing the business data in a secure container. Eliminate the need for manual logging, which creates vulnerabilities within the process.
- Continuous monitoring: the Department of Justice’s (DOJ) Evaluation of Corporate Compliance Programs (ECCP) emphasizes the ‘active’ nature of a strong surveillance program. AI-based analysis and proactive alerting flags risks in real-time, enabling your team to respond quickly and minimize the risks of misconduct.
- Audit-readiness: platforms must mandate a write-once, read-many format for a minimum of two years and ensure that firms can meet a reconstruction demand within 72-hours of the request.
Global Relay solutions help capture and monitor these communications in a clear, legible archive, including those under a BYOD policy.
With over 25 years of experience in recordkeeping and risk mitigation, Global Relay has developed purpose-built solutions designed to keep teams compliant without impeding business operations. Tackle evolving issues such as disappearing messages and inefficient e-Discovery with Global Relay for Healthcare and Life Sciences.
